RxDoctor Payments Data

Brian Alessi, MD

Internal Medicine · Rome, NYNPI 1154323012

Payments from drug & device makers

$3,700in general payments, 2019–2025

Across 217 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$876
  • GSK$575
  • Amgen$341
  • Sanofi$322
  • Novartis$271
  • Novo Nordisk$199
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,687100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,700 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$239,837
Medicare patients
329
Services billed
9,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab33$122,397
Repatha SureclickEvolocumab92$87,677
OzempicSemaglutide50$83,097
EliquisApixaban55$69,942
JanuviaSitagliptin Phosphate39$58,859
JardianceEmpagliflozin43$56,103
XareltoRivaroxaban37$51,653
TrulicityDulaglutide15$19,952
TradjentaLinagliptin13$18,530
Praluent PenAlirocumab18$18,469
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$16,976
MyrbetriqMirabegron12$15,146
SymbicortBudesonide/Formoterol Fumarate42$14,994
Repatha SyringeEvolocumab25$13,184
BelsomraSuvorexant12$5,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$199$83,09750 claims
Boehringer IngelheimJardiance, Tradjenta$35$74,63356 claims
PfizerEliquis$134$69,94255 claims
MerckJanuvia, Belsomra$24$64,18451 claims
Johnson & JohnsonXarelto$64$51,65337 claims
Lilly USA, LLCTrulicity$174$19,95215 claims
GSKTrelegy Ellipta$575$16,97621 claims
AstraZenecaSymbicort$876$14,99442 claims
AbbVieSynthroid$78$1,68548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rome

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →